

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Cecile BOUGERET et al.

Conf. Unassigned

Application No. **NEW NATIONAL PHASE**

Group: Unassigned

Filed: September 15, 2006

Examiner: Unassigned

For: METHOD FOR SCREENING AGENTS MODULATING I κ B α PROTEIN
UBIQUITINATION AND MEANS FOR CARRYING OUT SAID METHOD

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION CONCURRENT WITH THE
FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

September 15, 2006

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, and in fulfillment of the duty of disclosure under 37 C.F.R. § 1.56, applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- ☐ Copies of the U.S. patents or publications are not submitted since the USPTO has waived their submission for applications filed after June 30, 2003.
- ☐ Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☒ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should have been forwarded from the International Search Authority pursuant to the trilateral agreement between the USPTO, EPO and JPO, or they are U.S. patents or U.S. published applications. If copies are needed, please contact the undersigned.

10/592944

AP9/Rec'd PCT/PTO 15 SEP 2006

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☐ **DOCUMENTS IN THE ENGLISH LANGUAGE**

The attached non U.S. patents, non U.S. patent application publications, foreign publications, or other information in the English language do not require a statement of relevancy.

b. ☐ **DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ☒ **FOREIGN SEARCH REPORT OR ACTION**

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

d. ☐ **OTHER**

The following additional information is provided for the Examiner's consideration.

FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,

YOUNG & THOMPSON

Benoit Castel

Benoit Castel, Reg. No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

BC/sj

Enclosures: ☒ Form PTO-1449(s)
☐ Documents
☒ Foreign Search Report
☐ Other: _____

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Attorney Docket No.:

0510-1149

Application No.:

NEW NATIONAL PHASE

Applicant:

Cecile BOUGERET et al.

Filing Date:

September 15, 2006

Group Art Unit:

Unassigned

U.S. PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing date (if appropriate) |
|------------------|-----------------|------|------|-------|----------|------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Country | Class | Subclass | Translation | |
|------------------|-----------------|---------|---------|-------|----------|-------------|----|
| | | | | | | Yes | No |
| | 99/04033 | 01/1999 | WO | | | | |
| | 99/38969 | 08/1999 | WO | | | | |
| | 1,182,251 | 02/2002 | EP | | | | |
| | 98/36070 | 08/1998 | WO | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|--|---|
| | "SCFBETA – TRCP and Phosphorylation Dependent Ubiquitination of Ikappabalpha Catalyzed By UBC3 and UBC4", P. Strack et al., Oncogene, Basingstoke, Hants, GB, Vol. 19, 20 July 2000, pp. 3529-3536, XO999881550 ISSN: 0950-9232. |
| | "The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro", Jeffrey T. Winston et al., Genes and Development, Vol. 13, No. 3, 1 February 1999, pp. 270-283, XP002308533 ISSN: 0890-9369. |
| | "Inducible degradation of IkappaBalpha by the proteasome requires interaction with the F-box protein h-betaTrCP", Mathias Kroll et al., Journal of Biological Chemistry, Vol. 274, No. 12, 19 March 1999, pp. 7941-7945, Xp002308507, ISSN: 0021-9258. |
| | "New Targets for anti-inflammatory drugs", A. J. Lewis et al., Current Opinion In Chemical Biology, Current Biology Ltd., London, GB, Vol. 3, 1999, pp. 489-494, XP002197383 ISSN: 1367-5931. |
| | |
| | |

EXAMINER:

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* English language abstract provided for the Examiner's convenience